What smart money is saying about TransMedics
1 fund in our archive has pitched TransMedics, most recently Infuse AM in December 2025.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Get an email when a fund buys, sells or pitches it
Position history
Between Q4 2025 and Q2 2026, 2 fund letters reported a position in TransMedics, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 0 | 0 |
| Q4 2025 | 1 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 2 positions
- June 2026
“TransMedics Group (TMDX) detracted the most from our performance, as the company reported sales in-line with expectations but profitability was much lower than expected.”
TransMedics - December 2025
“The most significant detractors from the Portfolio’s relative performance in the quarter were Oddity Tech, Carpenter Technology, and TransMedics Group.”
TransMedics
Also mentioned · 1
These funds discuss TransMedics as a competitor, benchmark or comparable, without disclosing a position in it.
- MentionedGreystone Capital ManagementOctober 2026
“I’ll discuss Transmedics more below, but there are pros and cons to each approach, and although TMDX has the sticker model with more of a moat around it (as well as higher margins), the transplant industry is shifting in a direction that should favor Strata longer term.”
TransMedics
Fund coverage · 1 thesis
- Infuse AMDecember 2025
TransMedics is transforming organ transplants with a growing logistics network that lowers unit costs and could expand the market through DCD procedures, creating a density-driven moat.
Read the full thesis
Read every full thesis on TransMedics
Read all 1 thesis in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→